MIRA on Nasdaq

MIRA PHARMACEUTICALS, INC.

MIRA PHARMACEUTICALS, INC. is an American pharmaceutical preparations company based in Baltimore.2

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with another stock.

  • TickerMIRA on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersBaltimore, United States2
  • Incorporated inFL3
  • Business address1200 Brickell Avenue, Suite 1950 #1183, Miami, Fl 331313
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI5493000N6HPDY7V7OR152
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Panhans, Austin A, 33606 Tampa, United States2
  • Registered withFlorida Division of Corporations, P200000710612

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Net income567-$10.4M in 2025+48% since 2022
-$15.0M-$10.0M-$5.0M02022: -$7.1M-$7.1M20222023: -$12.0M-$12.0M2023+70%2024: -$7.9M-$7.9M2024−34%2025: -$10.4M-$10.4M2025+33%
Fiscal year202120222023202420252026
Research and development$2.4M5$1.6M6$3.3M7$1.7M7
Operating expenses$7.0M5$8.5M6$8.0M7$10.5M7
Interest$10.2K5$3.5M6-$165.7K6
Net income-$7.1M5-$12.0M6-$7.9M7-$10.4M7
Earnings per share-$0.405-$0.856-$0.517-$1.357
Earnings per share (diluted)-$0.405-$0.856-$0.517-$1.357
Shares (weighted, basic)17.6M shares513.9M shares615.4M shares723.7M shares7
Shares (weighted, diluted)17.6M shares513.9M shares615.4M shares6

Compare MIRA PHARMACEUTICALS, INC. with another company

Corporate structure

MIRA PHARMACEUTICALS, INC. sits at the top of its group. 3 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of MIRA PHARMACEUTICALS, INC.

  • Bay Shore Trust Filed SC 13D/A on MIRA PHARMACEUTICALS, INC., latest Dec 27, 2023 (4 filings since Aug 14, 2023)
  • MIRA PHARMACEUTICALS, INC. Baltimore, Maryland, United States
    • MIRAPHARM Acquisition, Inc. Subsidiary · Delaware, United States
    • SKNY Pharmaceuticals, Inc. Subsidiary · Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What MIRA PHARMACEUTICALS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$6.3M7 Dec 31, 2025$2.8M7 Dec 31, 2024+124.0%
Marketable securities, current$4.7M7 Dec 31, 2025

Properties, in its own words

Our current business address is 1200 Brickell Avenue, Suite 1950 #1183, Miami, Florida 33131, which is a virtual office.

Item 2 of the 10-K filed Mar 31, 2026.10

Leadership

Who has led MIRA PHARMACEUTICALS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Erez Aminov2023–now

Chair

  1. Erez Aminov2026–now

Chief financial officer

  1. Michelle Yanez2023–2024
  2. Alan Weichselbaum2025–2026
  3. Andriy Mushak2026–now
2025
Board members and other officers (10)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerJames McNulty, CPA named Aug 1, 202225
  • Executive OfficerJude Uzonwanne named Aug 1, 202225
  • Executive OfficerPaul Rivard, ESQ named Aug 1, 202225
  • DirectorChris Chapman, MD named Aug 1, 202225
  • DirectorHugh McColl III named Aug 1, 202225
  • DirectorJosh Silverman named Aug 1, 202225
  • DirectorTalhia Tuck, JD named Aug 1, 202225

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • MIRAPHARM Acquisition, Inc. Delaware4
  • SKNY Pharmaceuticals, Inc. Delaware4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Mira1a Therapeutics, Inc.Jun 29, 2022 to May 2, 20233

Timeline

  1. Sep 17, 20268-K Regulation FD disclosure26
  2. Sep 16, 20268-K Shareholder vote27
  3. Sep 1, 20268-K Regulation FD disclosure28
  4. Aug 6, 20268-K Regulation FD disclosure29
  5. Jul 31, 20268-K Listing notice or transfer30
  6. Jul 10, 20268-K Regulation FD disclosure31
  7. Jul 6, 20268-K Regulation FD disclosure32
  8. Jun 25, 20268-K Regulation FD disclosure33
  9. Jun 17, 20268-K Regulation FD disclosure34
  10. Jun 8, 20268-K Executive or director change35
  11. Jun 4, 20268-K Entered a material agreement; Regulation FD disclosure36
  12. May 27, 20268-K Entered a material agreement; Regulation FD disclosure37
  13. Aug 2, 2023New chief executive Erez Aminov becomes CEO11
  14. Sep 3, 2020Founded MIRA PHARMACEUTICALS, INC. is founded2

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/202638

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

195 filings to the SEC since October 2021: 5 annual reports, 11 quarterly reports, 72 major events, 54 insider forms, 4 large holders, 2 private raises, 47 other. The latest 20:

  1. Sep 17, 20268-K EDGAR
  2. Sep 16, 20268-K EDGAR
  3. Sep 1, 20268-K EDGAR
  4. Aug 12, 202610-Q EDGAR
  5. Aug 6, 20268-K EDGAR
  6. Jul 31, 20268-K EDGAR
  7. Jul 28, 2026DEF 14A EDGAR
  8. Jul 10, 20268-K EDGAR
  9. Jul 6, 20268-K EDGAR
  10. Jun 25, 20268-K EDGAR
  11. Jun 17, 20268-K EDGAR
  12. Jun 15, 20264 EDGAR
  13. Jun 15, 20264 EDGAR
  14. Jun 15, 20264 EDGAR
  15. Jun 15, 20264 EDGAR
  16. Jun 9, 20263 EDGAR
  17. Jun 8, 20268-K EDGAR
  18. Jun 4, 20268-K EDGAR
  19. May 27, 20268-K EDGAR
  20. May 14, 202610-Q EDGAR

The 195 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

18 open-market trades by officers, directors and large owners since October 2021: 3 buys and 15 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 16, 2025Aminov ErezChief Executive OfficerSale613,595$2.11$1.3MForm 4
Nov 20, 2024Aminov ErezChief Executive OfficerSale44,590$1.27$56.6KForm 4
Nov 19, 2024Aminov ErezChief Executive OfficerSale55,410$1.39$77.0KForm 4
Aug 28, 2024McNulty Brian Patrick10% ownerSale200,000$1.96$392.0KForm 4
May 21, 2024Aminov ErezChief Executive OfficerBuy8,700$0.94$8.2KForm 4
Dec 11, 2023McNulty Brian Patrick10% ownerSale46,005$1.55$71.3KForm 4
Dec 8, 2023McNulty Brian Patrick10% ownerSale19,053$1.61$30.7KForm 4
Dec 7, 2023McNulty Brian Patrick10% ownerSale33,333$1.89$63.0KForm 4
Dec 6, 2023McNulty Brian Patrick10% ownerSale27,733$2.95$81.8KForm 4
Dec 4, 2023McNulty Brian Patrick10% ownerSale61,331$3.98$244.1KForm 4
Nov 30, 2023McNulty Brian Patrick10% ownerSale4,842$3.77$18.3KForm 4
Nov 29, 2023McNulty Brian Patrick10% ownerSale7,399$3.98$29.4KForm 4
Nov 28, 2023McNulty Brian Patrick10% ownerSale241$4.00$964Form 4
Nov 27, 2023McNulty Brian Patrick10% ownerSale6,425$4.00$25.7KForm 4
Nov 21, 2023McNulty Brian Patrick10% ownerSale5,000$5.00$25.0KForm 4
Nov 20, 2023McNulty Brian Patrick10% ownerSale26,733$5.07$135.5KForm 4
Aug 7, 2023Bay Shore Trust10% ownerBuy119,048$7.00$833.3KForm 4
Aug 2, 2023Bay Shore Trust10% ownerBuy157,170$7.00$1.1MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Erez Aminov,48$438.8K$5.3M40
2025Alan Weichselbaum,$37.0K$124.3K40
2025Michelle Yanez,$104.7K$116.7K40
2024CEO$260.0K$3.1M40
2024Former CFO$158.2K$444.0K40

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 22, 2022Raised $625,000 in a private offering of equity Form D: $3 million offered in all Form D
  2. Nov 9, 2021Raised $6.5 million in a private offering of equity Form D: 76 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 26. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC751,801$712.0K0.0%+57,889
Cross Staff Investments Inc359,401$340.2K0.2%No change
Geode Capital Management, LLC303,882$287.6K0.0%+12,992
BlackRock, Inc.244,622$231.5K0.0%+132,276
Vanguard Fiduciary Trust Co170,668$161.6K0.0%+1,185
Captrust Financial Advisors90,645$85.8K0.0%New
Northern Trust Corp67,735$64.1K0.0%+37
First American Bank60,000$56.8K0.0%No change
Commonwealth Equity Services, LLC53,189$50.3K0.0%+18,122
State Street Corp49,100$46.5K0.0%No change
International Assets Investment Management, LLC35,000$33.2K0.0%No change
Fifth Third Bancorp20,000$18.9K0.0%No change
Citadel Advisors LLC18,661$17.7K0.0%New
Susquehanna International Group, Llp18,566$17.6K0.0%−6,580
Mariner, LLC16,500$15.6K0.0%No change
XTX Topco Ltd16,374$15.5K0.0%−21,199
Cary Street Partners Financial LLC10,000$9.5K0.0%No change
Federation des caisses Desjardins du Quebec8,000$7.6K0.0%No change
Osaic Holdings, Inc.2,000$1.9K0.0%No change
UBS Group AG1,772$1.7K0.0%−4,684
Citigroup Inc1,207$1.1K0.0%−3,019
Steward Partners Investment Advisory, LLC1,000$9470.0%−1,000
Tower Research Capital LLC (TRC)517$4890.0%−4,459
Barclays PLC159$1500.0%New
Hrt Financial LP13,450$120.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How MIRA PHARMACEUTICALS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMIRA PHARMACEUTICALS, INC.1
  • CIK0001904286
  • Employer ID (EIN)85-335454710
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company10
  • Incorporated inFlorida10
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1200 Brickell Avenue, Suite 1950 #1183, Miami, FL 331311
  • Mailing address324 South Hyde Park Avenue, Suite 350, Tampa, FL 336061
  • Phone813-369-51501
  • Shares outstanding42,022,087 as of Aug 10, 20269
  • Public float$16.0M as of Jun 30, 202510
  • AuditorSALBERG & COMPANY, P.A., Boca Raton, Florida PCAOB ID 106; it also attests to the company’s internal control over financial reporting10
  • On EDGAR sinceJun 29, 20221
  • Filings196 in all: 8-K (72), 4 (34), 3 (20), 10-Q (10), CORRESP (7), S-1/A (5), UPLOAD (5), 10-K (3)1
    All 34 form types

    424B5 (3), EFFECT (3), SC 13D/A (3), 10-K/A (2), 144 (2), 424B3 (2), D (2), DEF 14A (2), DEFA14A (2), DRS/A (2), S-1 (2), 10-Q/A (1), 144/A (1), 424B1 (1), 424B4 (1), 5 (1), 8-A12B (1), CERT (1), DEFM14A (1), DRS (1), DRSLTR (1), PREM14A (1), PRER14A (1), S-3 (1), S-8 (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 12, 2026
    Proxy statement (DEF 14A) Jul 28, 2026
    Latest 8-K (8-K) Sep 17, 2026

Securities registered for trading

ClassSymbolExchange
Common stock, par value $0.0001MIRANasdaq

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).10

Risk factors and legal proceedings

The risks MIRA PHARMACEUTICALS, INC. names in Item 1A of its 10-K filed Mar 31, 2026: 72 risks under these headings, as written.10

  • Risks Related to Our Operations and Financial Condition
  • We are an early development-stage company with no revenues.
  • The report of our independent registered accounting firm on our audited financial statements for the fiscal year ended December 31, 2025 contains an explanatory paragraph relating to our ability to continue as a going concern.
  • Because we have a limited operating history, you may not be able to accurately evaluate our operations.
  • We have significant and increasing liquidity needs and will require additional funding.
  • We have yet to generate revenues or achieve a profit and may not generate revenue or achieve a profit for many years, if at all.
  • Conflicts of interest may arise between us and MIRALOGX.
  • Certain of our executive officers will not be employed by us on a full-time basis.
  • Risks Relating to Our Business and Our Industry
  • We are dependent on our current and future product candidates, some of which may not receive regulatory approval or be successfully commercialized.
  • Results of pre-clinical studies and earlier clinical trials are not necessarily predictive indicators of future results.
  • Our product candidates, if approved, may be unable to achieve the expected market acceptance and, consequently, limit our ability to generate revenue from new products
The other 62 risks
  • If product liability lawsuits are successfully brought against us, we will incur substantial liabilities and may be required to limit the commercialization of Ketamir-2 and MIRA-55 and our product candidates.
  • Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
  • Legislative or regulatory reform of the health care system in the U.S. may affect our ability to profitably sell our products, if approved.
  • Unfavorable global economic and geopolitical conditions could adversely affect our business, financial condition, stock price, and results of operations.
  • Risks Related to Development and Regulatory Approval of Our Product Candidates
  • Clinical trials for our product candidates are expensive, time-consuming, uncertain, and susceptible to change, delay or termination. The results of clinical trials are open to differing interpretations.
  • Clinical trials of synthetic cannabinoid drug candidates and ketamine analogs are novel with very limited or non-existing history; we face a significant risk that the trials will not result in commercially viable drugs and treatments.
  • The regulatory approval processes with the FDA are lengthy and inherently unpredictable.
  • There is a high rate of failure for drug candidates proceeding through clinical trials.
  • Risks Related to Our Reliance Upon Third Parties
  • Our existing collaboration arrangements and any that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our product candidates.
  • We depend on a limited number of suppliers for materials and components required to manufacture our product candidates.
  • We rely on, and expect to continue to rely on, third parties to conduct clinical trials for our product candidates.
  • Risks Related to Our Intellectual Property
  • We may not be able to adequately protect our product candidates or our proprietary technology in the marketplace.
  • We have no patent protection for MIRA-55, which could adversely impact MIRA-55’s potential competitive position.
  • Risks Related to SKNY and SKNY-1
  • SKNY has yet to generate revenues or achieve a profit and may not generate revenue or achieve a profit for many years, if at all.
  • SKNY does not own rights to SKNY-1
  • Conflicts of interest may arise between SKNY and MIRALOGX.
  • Risks Relating to the Ownership of our Common Stock
  • Because of the speculative nature of investment risk, you may lose your entire investment.
  • Certain of our founding stockholders, plus our existing officers and directors, control a substantial interest in us and thus may influence certain actions requiring stockholder vote.
  • Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock.
  • If we fail to maintain compliance with Nasdaq Listing Rules, our shares may be delisted from Nasdaq, which would result in a limited trading market for our shares and make obtaining future debt or equity financing more difficult for the us.
  • We are an early development-stage company with no revenues. As such, our losses from operations and negative cash flows as of December 31, 2025 raise substantial doubt about our ability to continue as a going concern absent obtaining adequate new debt or equity financings.
  • Operating results may vary significantly in future periods.
  • Our future viability will largely depend on the positive development of Ketamir-2 and MIRA-55, and any future product candidates, which development will require significant capital resources and years of clinical development effort.
  • Impact of global tensions may increase uncertainty of our future operations.
  • We have limited marketing experience, and we do not anticipate at this time establishing a sales force or distribution and reimbursement capabilities, and we may not be able to successfully commercialize any of our product candidates if they are approved in the future.
  • Our product candidates, if approved, may be unable to achieve the expected market acceptance and, consequently, limit our ability to generate revenue from new products.
  • If the price for any future approved products decreases or if government and other third-party payers do not provide coverage and adequate reimbursement levels, our revenue and prospects for profitability will suffer.
  • We expect to face intense competition, often from companies with greater resources and experience than we have.
  • Product shipment delays could have a material adverse effect on our business, results of operations and financial condition.
  • The manufacture of our product candidates is complex and uncertain, and until we develop a validated manufacturing process, we may encounter difficulties in supplying our planned and future clinical trials. If we encounter such difficulties, or fail to meet quality standards, our ability to meet clinical timelines and expand our development strategy could be impacted.
  • We may fail to expand our manufacturing capability in time to meet market demand for our products and product candidates, and the FDA may refuse to accept our facilities or those of our contract manufacturers as being suitable for the production of our products and product candidates. Any problems in our manufacturing process could have a material adverse effect on our business, results of operations and financial condition.
  • Business interruptions could delay us in the process of developing our product candidates and could disrupt our product sales.
  • Counterfeit versions of our products could harm our business.
  • We depend upon our key personnel and our ability to attract and retain employees.
  • We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, results of operations and financial condition.
  • Our proprietary information, or that of our suppliers and business partners, may be lost or we may suffer security breaches.
  • Failure of our information technology systems, including cybersecurity attacks or other data security incidents, could significantly disrupt the operation of our business.
  • Security breaches, loss of data and other disruptions could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability, which could adversely affect our business and our reputation.
  • We expect additional federal and state legislative proposals for health care reform, which could limit the prices that can be charged for the products we develop and may limit our commercial opportunity.
  • We may acquire other companies which could divert our management’s attention, result in additional dilution to our shareholders and otherwise disrupt our operations and harm our operating results.
  • We are subject to federal and state healthcare laws and regulations and implementation of or changes to such healthcare laws and regulations could adversely affect our business and results of operations.
  • We plan to conduct clinical trials at sites outside the United States. The FDA may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense.
  • If we are found in violation of federal or state “fraud and abuse” laws, we may be required to pay a penalty and/or be suspended from participation in federal or state health care programs, which may adversely affect our business, financial condition, and results of operations.
  • Serious adverse events or other safety risks could require us to abandon development and preclude, delay or limit approval of our product candidates, limit the scope of any approved label or market acceptance, or cause the recall or loss of marketing approval of products that are already marketed.
  • We depend on a limited number of suppliers for materials and components required to manufacture our product candidates. The loss of these suppliers, or their failure to supply us on a timely basis, could cause delays in our current and future capacity and adversely affect our business.
  • We rely on, and expect to continue to rely on, third parties to conduct clinical trials for our product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize our product candidates, and our business could be substantially harmed.
  • We rely and expect to continue to rely on third parties to manufacture our clinical product supplies and clinical candidates, and we may rely on third parties for at least a portion of the manufacturing process of our product candidates, if approved. Our business could be harmed if those third parties fail to provide us with sufficient quantities of product supplies or product candidates or fail to do so at acceptable quality levels or prices.
  • If third parties claim that our intellectual property, products, processes, or anything else used by us infringes upon their intellectual property, our operating profits could be adversely affected.
  • If we are unable to obtain and maintain intellectual property protection for our technology and products, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.
  • SKNY does not own rights to SKNY-1.
  • SKNY’s rights to SKNY-1 are subject to royalties.
  • SKNY’s product candidates, if approved, may not achieve the expected market acceptance and, consequently, limit SKNY’s ability to generate revenue.
  • SKNY expects to face intense competition, often from companies with greater resources and experience than it has.
  • We are dependent on SKNY’s current and future product candidates, some of which may not receive regulatory approval or be successfully commercialized.
  • The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain executive management and qualified board members.
  • We are an “emerging growth company,” and any decision on our part to comply only with certain reduced reporting and disclosure requirements applicable to emerging growth companies could make shares of our common stock less attractive to investors.
  • If our shares were to be delisted from Nasdaq, they may become subject to the SEC’s “penny stock” rules.
  • Some provisions of Florida law and our amended and restated articles of incorporation and amended and restated bylaws may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our shareholders and may prevent attempts by our shareholders to replace or remove our current management.
  • Our amended and restated bylaws designates the state courts located within the state of Florida as the exclusive forum for substantially all disputes between us and our shareholders and the federal district courts as the exclusive forum for Securities Act claims, which could limit our shareholders’ ability to obtain a favorable judicial forum for disputes with us.
  • Securities or industry analysts may not regularly publish reports on us, which could cause the price of our securities or trading volumes to decline.
  • We will likely conduct further offerings of our equity securities in the future, in which case your proportionate interest may become diluted.
  • We may issue shares of preferred stock in the future, which could make it difficult for another company to acquire us or could otherwise adversely affect holders of our common stock, which could depress the price of our common stock.
  • We have never declared or paid any cash dividends or distributions on our capital stock. We do not anticipate paying any cash dividends on our common stock in the foreseeable future.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40